Efficacy of modified diode transscleral cyclophotocoagulation in patients with painful neovascular glaucoma secondary to retinal vein occlusion
DOI:
https://doi.org/10.31288/oftalmolzh20253310Keywords:
diode laser, transscleral cyclophotocoagulation, neovascular glaucoma, retinal vein occlusion, intraocular pressure, retinaAbstract
Purpose: To assess the efficacy (success rate) of modified diode transscleral cyclophotocoagulation (TSCPC) in patients with painful neovascular glaucoma (NVG) secondary to retinal vein occlusion (RVO).
Material and Methods: This prospective, single-center cohort study included 62 patients (62 eyes) with NVG secondary to RVO. Best-corrected visual acuity (BCVA), the number of intraocular pressure (IOP)-lowering medications, laboratory characteristics and pain scores were assessed. A diode laser TSCPC with a fiber optic G-probe was performed at a power of 1,000 mW for duration of 1.5 s (corresponding to 1.5 J/pulse). Post-TSCPC measures of success included IOP between 10 and 21 mmHg or a reduction in IOP of ≥ 30% from baseline IOP, no ocular pain and improvement in or maintenance of BCVA.
Results: At 12 months after TSCPC, the IOP decreased by 48% (р = 0.000). Eight (13%), 18 (29%), and 7 (11%) eyes received two, three, and four CPC sessions, respectively. Post-TSCPC complications included long-term inflammation was noted in 6 eyes (9.7%) and hyphema in 1 eye (1.6%). Multivariate regression analysis demonstrated that TSCPC success depended on the baseline IOP (р = 0.01), number of local IOP-lowering medications (р = 0.03), and presence of preoperative complications (р = 0.02), and was associated with a D-dimer value < 0.55 mg fibrinogen equivalent units/l (р = 0.01). Panretinal laser photocoagulation performed early (within 3 months) after RVO and combined with antiangiogenic therapy did not prevent NVG, but contributed to the success of TSCPC for NVG.
Conclusion: The success rate of modified diode TSCPC in patients with painful NVG secondary to RVO at 12 months was 71%. Modified diode TSCPC in painful NVG secondary to RVO appears to be safe in terms of the absence of serious complications (hypotony and phthisis bulbi). TSCPC success depends on the presence of ophthalmic and systemic complications which should be treated.
References
Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007 Sep;26(5):470-85. doi: 10.1016/j.preteyeres.2007.06.001. https://doi.org/10.1016/j.preteyeres.2007.06.001
Miglani T, Ullah S. A Review of the Surgical Management of Neovascular Glaucoma. Curr Surg Rep. 2023;11:162-167. https://doi.org/10.1007/s40137-023-00358-9
Ndulue JK, Rahmatnejad K, Sanvicente C, Wizov SS, Moster MR. Evolution of Cyclophotocoagulation. J Ophthalmic Vis Res. 2018;13(1):55-61. https://doi.org/10.4103/jovr.jovr_190_17
Chen MF, Kim CH, Coleman AL. Cyclodestructive procedures for refractory glaucoma. Cochrane Database Syst Rev. 2019;3(3):223. https://doi.org/10.1002/14651858.CD012223
Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007;91(12):1631-1635. https://doi.org/10.1136/bjo.2007.116533
Ramli N, Htoon HM, Ho CL, Aung T, Perera S. Risk factors for hypotony after transscleral diode cyclophotocoagulation. J Glaucoma. 2012;21(3):169-173. https://doi.org/10.1097/IJG.0b013e318207091a
Duerr ER, Sayed MS, Moster S, et al. Transscleral diode laser cyclophotocoagulation: a comparison of slow coagulation and standard coagulation techniques. Ophthalmol Glaucoma. 2018;1(2):115-122. https://doi.org/10.1016/j.ogla.2018.08.007
Modified Settings for Transscleral Cyclophotocoagulation of the Ciliary Body in Glaucoma: A Randomized Controlled Trial. Study of quality of life after glaucoma surgery. ClinicalTrials.gov Identifier: NCT02875158. [Internet]. Available from: Accessed August 08, 2024. https://clinicaltrials.gov/study/NCT02875158.
Guzun O, Zadorozhnyy O, Nasinnyk I, Chargui W, Oueslati Y, Korol A. Efficacy of Nd:YAG and diode laser transscleral cyclophotocoagulation in the management of neovascular glaucoma associated with proliferative diabetic retinopathy. J.ophthalmol. (Ukraine). 2024;3:8-15. https://doi.org/10.31288/oftalmolzh20243815
Guzun OV, Zadorozhnyy OS, Chechin PP, Artemov OV, Chargui W, Korol AR. Comparing histopathological effects of the neodymium and diode laser transscleral cyclophotocoagulation: an experimental study. J.ophthalmol. (Ukraine). 2024;5:32-7. https://doi.org/10.31288/oftalmolzh202453237
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(11):S240-52. https://doi.org/10.1002/acr.20543
Vaidya R, Washington A, Stine S, Geamanu A, Hudson I. The IPA, a Modified Numerical System for Pain Assessment and Intervention. J Am Acad Orthop Surg Glob Res Rev. 2021;5(9):e21.00174. https://doi.org/10.5435/JAAOSGlobal-D-21-00174
Zadorozhnyy O, Guzun O, Kustryn T, Nasinnyk I, Chechin P, Korol A. Targeted transscleral laser photocoagulation of the ciliary body in patients with neovascular glaucoma. J Ophthalmol (Ukraine). 2019;4:3-7. https://doi.org/10.31288/oftalmolzh2019437
Bernardi E, Töteberg-Harms M. MicroPulse Transscleral Laser Therapy Demonstrates Similar Efficacy with a Superior and More Favorable Safety Profile Compared to Continuous-Wave Transscleral Cyclophotocoagulation. J Ophthalmol.2022;8566044. https://doi.org/10.1155/2022/8566044
Guzun O, Zadorozhnyy O, Wael C. Current Strategy of Treatment for Neovascular Glaucoma Secondary to Retinal Ischemic Lesions. J Ophthalmol (Ukraine). 2024;2:32-39. https://doi.org/10.31288/oftalmolzh202423239
Walland MJ. Diode laser cyclophotocoagulation: longer term follow up of a standardized treatment protocol. Clin Exp Ophthalmol. 2000;28(4):263-267. https://doi.org/10.1046/j.1442-9071.2000.00320.x
John T, Sassani JW, Eagle RC. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;90(6):721-728. https://doi.org/10.1016/S0161-6420(83)34520-6
Zemba M, Dumitrescu OM, Vaida F, et al. Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma. Exp Ther Med. 2022;23(4):278. https://doi.org/10.3892/etm.2022.11207
Nabili S, Kirkness CM. Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma. Eye. 2004;18(4):352-356. https://doi.org/10.1038/sj.eye.6700644
Schulze Schwering M, Kayange P, Klauss V, Kalua K, Spitzer MS. Low-dose transscleral diode laser cyclophotocoagulation (TSCPC) as a potential single treatment for primary open-angle glaucoma (POAG) in Malawi?. Graefes Arch Clin Exp Ophthalmol. 2013;251(10):2389-2393. https://doi.org/10.1007/s00417-013-2441-1
Khodeiry MM, Liu X, Sheheitli H, et al. Slow coagulation transscleral cyclophotocoagulation for postvitrectomy patients with silicone oil-induced glaucoma. J Glaucoma. 2021;30(9):789-94. https://doi.org/10.1097/IJG.0000000000001893
Hwang YH, Lee S, Kim M, Choi J. Comparison of treatment outcomes between slow coagulation transscleral cyclophotocoagulation and micropulse transscleral laser treatment. Sci Rep. 2024;14(1):23944. https://doi.org/10.1038/s41598-024-75246-y
Qu S, Zou Y, Yang L, Wu H. The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion. Front Med (Lausanne). 2024;10:1280776. https://doi.org/10.3389/fmed.2023.1280776
Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115:1571-80, 1580.e1-3. 10.1016/j.ophtha.2008.02.026 https://doi.org/10.1016/j.ophtha.2008.02.026
SooHoo J, Seibold L, Pantcheva M, Kahook M. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015; 43:803-7. 10.1111/ceo.12559. https://doi.org/10.1111/ceo.12559
Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008;28(5):696-702. https://doi.org/10.1097/IAE.0b013e3181679c0b
Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. Am J Hematol. 2019;94(7):833-839. https://doi.org/10.1002/ajh.25482
Tayal D, Jain P, Goswami B. D-dimer - a multifaceted molecule. Horm Mol Biol Clin Investig. 2024;45(2):75-84. https://doi.org/10.1515/hmbci-2022-0093
Su X, Zheng D, Wang M, Zuo Y, Wen J, Zhai Q, et al. Low density lipoprotein cholesterol is associated with increased risk of cardiovascular disease in participants over 70 years old: A prospective cohort study. Nutr Metab Cardiovasc Dis. 2022;32(2):447-455. https://doi.org/10.1016/j.numecd.2021.10.009
Hayreh SS, Podhajsky PA, Zimmerman MB. Retinal artery occlusion: associated systemic and ophthalmic abnormalities. Ophthalmology. 2009;116(10):1928-36. https://doi.org/10.1016/j.ophtha.2009.03.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Guzun O.V., Zadorozhnyy O.S., Nasinnyk I.O., Korol A.R.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
.png)
